This study investigated the therapeutic effect of Alantolactone (Ala) on Nonalcoholic fatty liver disease (NAFLD). C57BL/6 mice were fed a high-fat diet (HFD) to induce NAFLD, then treated with Ala. Ala significantly inhibited inflammation, fibrosis, and oxidative stress in HFD-induced mice and palmitic acid (PA)-induced AML-12 cells. Mechanistically, Ala's effect was linked to Nrf2 induction and NF-κB inhibition. These findings suggest Ala is a potential therapy for NAFLD by blocking inflammation and oxidative stress.
Publisher
Nutrition and Diabetes
Published On
Jun 10, 2024
Authors
Jiong Wang, Yucheng Jiang, Leiming Jin, Chenchen Qian, Wei Zuo, Jianjun Lin, Longteng Xie, Bo Jin, Yanni Zhao, Lijiang Huang, Yi Wang
Tags
Alantolactone
Nonalcoholic fatty liver disease
NAFLD
inflammation
oxidative stress
C57BL/6 mice
therapeutic effect
Related Publications
Explore these studies to deepen your understanding of the subject.